ALTAltimmune, Inc.

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

Altimmune reports positive Phase 2 AUD data and rapid progress in its MASH Phase 3 trial, backed by $519 million in cash.

Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD. Chairman and Chief Executive Office

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

Moby summary of Altimmune, Inc.'s Q2 2026 earnings call

Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.

Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.

Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock.

Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.

Earlier on Tuesday, Altimmune said the mid-stage RECLAIM trial met its main goal and key secondary goals.

Altimmune (NASDAQ:ALT) reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying the study met its primary endpoint and several secondary measures after 24 weeks of treatment. The

Altimmune’s Phase 2 trial showed Pemvidutide reduced heavy drinking by 4.20 days per week compared with the placebo’s 2.75 days.

Altimmune Inc. (NASDAQ:ALT) shares climbed 18% on Tuesday after the biotechnology company reported positive topline data from its Phase 2 RECLAIM study evaluating pemvidutide as a treatment for alcohol use disorder.

Water Tower Research has initiated coverage of Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), the London-listed biopharmaceutical company developing ketamine-based treatments for alcohol use disorder. Analysts framed Solvonis as a late clinical-stage company trading at a microcap valuation...